TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adverse Events as Assessed by NCI CTCAE v 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence Rate of Local Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Transfer to Intensive care unit (ICU)
Endpoint domain: Mortality/survival
Primary endpoint: Need for Mechanical Ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Anthropometric Variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in energy and protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toxicity of MR-Guided fiducial marker placement
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in blood glucose (mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects Delivering at a Study Site
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Subjects Delivering at a Non-study Site
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in MENQOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ropinirole AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ropinirole maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients not requiring conversion to general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Direct costs associated with switching therapies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Who Achieved Sputum Culture Conversion (SCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximal Peak Concentration (Tmax) for Delamanid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Peak Concentration (Cmax) for Delamanid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in whole body and peripheral insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Speed Test (10 meter sprint test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agility T-Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lead failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Twenty-four (24) Hour Dry Sputum Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of Scleral Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse cosmetic outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Difference of tear film function as NIBUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of optical quality as scattering index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the frequency of ALDHhiSSClowCD133+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage enhancement of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with blood pressure <140/90 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute stroke treatment rate (tPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of patients with breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in beta-cell function (C-peptide level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Major response (hemoglobin increase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sperm number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pain of scrotum
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast to Noise Ratio (CNR) Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Seroprotected Against YF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in total score of Motor Function Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse tendency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary operator radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day in hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent vitreous hemorrhage incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision Stability While Doing Tasks on Mobile Phone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision Stability While Doing Tasks on Desktop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision Stability While Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplant-related mortality by day +100 and by one year post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Hematopoietic recovery by day +100 post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of the regimen acc. to Bearman scale
Endpoint domain: Adverse events/effects
Primary endpoint: Blood plasma levels of HDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uterine artery Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Efficacy of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACL Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 7-day smoking abstinence - 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported 7-day smoking abstinence - 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in renal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HIV viral load in the genital tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hamilton Depression Rating Scale 21 items (HDRS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: combined morbidity-mortality rate (CMMR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with adverse events of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Change in intake of the target vegetable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sore throat intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher Order Aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Intra-Ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or 4 Radiation Dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax,ss of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCtau of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax,ss of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCtau of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax,ss of EXP3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCtau of EXP3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRI staging accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical outcomes post-TME surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response Rate Including Complete Response, Partial Response, and Hematological Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Grade 3 or 4 Drug-related Non-hematologic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: daily gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery of FVIII 30 min after administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual plasma concentration of sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of severe adverse effects (grades 3-5)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete or Partial Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with severe postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of SUVmax (Maximal Standardized Uptake Value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of failure defined by obstructive symptoms or disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of attendance, retention, and discontinuation from DBSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With Grade 3 or Higher Toxicities Attributable to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid relapse rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of DNIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h-ambulatory mean arterial pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with postoperative infections
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Hepatomegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants Reporting an Adverse Event (AE) Leading to Dose Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in short-term recovery and functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: participant attendance and satisfaction with the group sessions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number/Percentage of Subjects With Demonstrated Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Supraglottic Airway Device Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Motor function of the paretic hand evaluated with the Jebsen-Taylor test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients able to comply with the protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Liver Status I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Status II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ablation time to achieve conduction block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pelvic Floor Muscle Strength with Perineometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The amount of leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastrointestinal Symptom Rating Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distinction between healthy controls and lung cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative recovery of radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative recovery of radioactivity in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transition Evaluation Questionnaire (TEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with dose limiting toxicity (DLT) for Part A1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with DLT for Part A2
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Luminal Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: HIV Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom Use Frequency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: PEP Use / Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PrEP Use / Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sexual Partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in arterial CO2 (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent abnormal clinical laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in corrected QT interval (QTc) duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eastern Cooperative Oncology Group (ECOG) Performance Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prepulse Inhibition (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mismatch Negativity (MMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gamma Auditory Steady-state Response (ASSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lower limb alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 24-hour Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to daily inhaled steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in laboratory results
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Effect-time Curve Over 96 Hours (AUEC[0-96 h]) for International Normalized Ratio (INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Maximum Observed Effect (Emax) of International Normalized Ratio (INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Maximum Observed Effect (Emax) in Factor VII Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of symptomatic intracerebral hemorrhage (Cochrane definition)
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of symptomatic intracerebral hemorrhage (SITS-MOST definition)
Endpoint domain: Mortality/survival
Primary endpoint: Stool diary parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Cognitive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Size of aphthous ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of RAS outbreaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral pain related to aphthous ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of nocturnal leg cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional MRI BOLD responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SUSAR
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mediterranean Diet adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in physical activity engagement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ergonomic performance during endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in Symptoms of Anxiety (Decrease in HAM-A Score >=50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in whole gut transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: % of Photos Identified Correctly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bladder wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improvement of lower urinary tract symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Alpha Oscillation Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Stress Incontinence Episode Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Viral load in tracheal aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HDL levels after hCG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL levels after hCG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol levels after hCG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of advanced care planning videos completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colonoscopy polyp and cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived Self-efficacy for Condom Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Complete Response Rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased Female Sexual Function Index Lubrication Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness in promoting healthy lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with elevated serum amyloid A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User Acceptance measured by adherence to diet and nutrition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Respiratory Severity Score (MAP X FiO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of flavocoxid compared to naproxen and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of flavocoxid compared to naproxen and placebo
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction during colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Pain Scale at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Pain Scale at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Frequency at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Frequency at 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary mortality of hypertension
Endpoint domain: Mortality/survival
Primary endpoint: Rate of VTE occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants With Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: EDSS (Expanded Disability Status Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With Ocular and Non-Ocular Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects